Synplogen and Ginkgo Bioworks Announce Collaborative Efforts to Boost Worldwide DNA Manufacturing and Gene Therapy Platform Services in Japan

Synplogen Co., a synthetic biology startup emerging from Kobe University's Graduate School of Science, Technology, and Innovation, is set to collaborate with Ginkgo Bioworks (NYSE: DNA), a company at the forefront of developing a platform for cell programming and biosecurity. The two entities have formally entered into a non-binding Memorandum of Understanding ("MOU") with the shared objective of accelerating the global advancement of DNA manufacturing and gene therapy platform services within Japan.

The collaborative efforts between Ginkgo and Synplogen will involve exploring potential global business partnerships in the field of DNA manufacturing. Synplogen's OGAB™ DNA synthesis services, known for their ability to synthesize DNA of various lengths, up to 100 kbp, and handle complex DNA synthesis, including high/low guanine-cytosine content and repeat sequences, will play a significant role in this venture.

Moreover, the partnership aims to extend the accessibility of Ginkgo's gene therapy services in the Japanese market. Synplogen intends to support this expansion by providing business development and marketing assistance, fostering connections between Ginkgo's services and Japanese biotechnology and pharmaceutical companies. Ginkgo, equipped with its end-to-end AAV gene therapy development platform and unique expertise in high-throughput design and synthesis optimization, seeks to drive progress in the Japanese bioeconomy.

Jason Kelly, co-founder and CEO of Ginkgo Bioworks, expressed excitement about the collaboration, highlighting Japan's historical leadership in bioeconomy innovations. He emphasized the partnership with Synplogen as a means to grow their cell and gene therapy service offerings in Japan while contributing to the dynamic and inventive Japanese bioeconomy.

Kazuhiko Yamamoto, Representative Director and CEO of Synplogen, conveyed his appreciation for the recognition of their DNA synthesis technology by Ginkgo Bioworks, a global leader in biofoundry. He looks forward to the positive impact of Ginkgo's contributions in driving growth within Japan's bioeconomy, aligning seamlessly with Synplogen's commitment to advancing innovative solutions in the Japanese biotech sector.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!